



## Correction to: Tumor-host interface in oral squamous cell carcinoma: Impact on nodal metastasis and prognosis

Rishikesh Thakur<sup>1</sup> · Alok Thakar<sup>1</sup> · Rajeev K. Malhotra<sup>2</sup> · Atul Sharma<sup>3</sup> · Aanchal Kakkar<sup>4</sup>

Published online: 4 May 2021  
© Springer-Verlag GmbH Germany, part of Springer Nature 2021

**Correction to:** European Archives of  
Oto-Rhino-Laryngology  
<https://doi.org/10.1007/s00405-021-06756-y>

In the original publication of the article, under the Table 2, values of Recurrences and Loco-regional was published incorrectly. The correct Table 2 is provided below,

---

The original article can be found online at <https://doi.org/10.1007/s00405-021-06756-y>.

- 
- ✉ Alok Thakar  
drathakar@gmail.com
  - ✉ Aanchal Kakkar  
aanchalkakkar@gmail.com

<sup>1</sup> Department of Otorhinolaryngology and Head and Neck Surgery, All India Institute of Medical Sciences, Ansari Nagar, New Delhi 110029, India

<sup>2</sup> Delhi Cancer Registry, BR Ambedkar Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India

<sup>3</sup> Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi, India

<sup>4</sup> Department of Pathology, All India Institute of Medical Sciences, Ansari Nagar, New Delhi 110029, India

**Table 2** Comparison of Brandwein-Gensler histological risk score groups with clinicopathological parameters and oncologic outcome

	Low risk (n=25)	Intermediate risk (n=93)	High risk (n=60)	p value <sup>a</sup>
Demographic parameters				
Mean age	53 years	48 years	44 years	<b>0.030<sup>b</sup></b>
Male: Female	23: 2	82: 11	50: 10	0.57
Tumor subsite	Group I: 3 Group II: 22	Group I: 32 Group II: 61	Group I: 32 Group II: 28	<b>0.001</b>
Tobacco consumption Yes: No	23: 2	86:7	53:7	0.440
Histopathological parameters				
Pathological T stage	T1: 4 T2: 9 T3: 6 T4: 6	T1: 17 T2: 30 T3: 19 T4: 27	T1: 10 T2: 22 T3: 9 T4: 19	0.95
Pathological node stage	N0: 24 N1: 1 N2: 0	N0: 59 N1: 14 N2: 20	N0: 4 N1: 35 N2: 21	<b>0.000</b>
Pathological TNM stage group (AJCC 8th edition)	I: 4 II: 9 III: 6 IV: 6	I: 13 II: 18 III: 22 IV: 40	I: 3 II: 1 III: 27 IV: 29	<b>0.000</b>
Histological grade	WDSCC: 20 MDSCC: 5 PDSCC: 0	WDSCC: 36 MDSCC: 55 PDSCC: 2	WDSCC: 12 MDSCC: 44 PDSCC: 4	<b>0.001</b>
Margin status	Clear: 12 Close: 13 Involved: 0	Clear: 44 Close: 46 Involved: 3	Clear: 31 Close: 26 Involved: 3	0.760
Oncology Outcomes				
Recurrences	2 (8%)	32 (34.4%)	35 (58.3%)	<b>0.001</b>
Loco-regional	2	21	23	
Distant	Nil	11	12	
2-year DFS	96%	51.6%	15%	<0.001 <sup>c</sup>
Early stage	100%	81.7%	25%	<0.001 <sup>c</sup>
Late stage	91.7%	33.9%	14.3%	0.001 <sup>c</sup>
2-year OS	96%	66.7%	31.3%	<0.001 <sup>c</sup>
Early stage	100%	90.3%	75%	0.214 <sup>c</sup>
Late stage	91.7%	54.8%	28.1%	<0.001 <sup>c</sup>
2-year LRC	96%	57.3%	18.7%	<0.001 <sup>c</sup>
2-year DSS	96%	67%	33%	<0.001 <sup>c</sup>

WD well differentiated, MD moderately differentiated, PD poorly differentiated, DFS disease-free survival, LRC Locoregional Control, DSS disease specific survival, OS overall survival, Group I subsites Tongue, Floor of mouth, Group II subsites Alveolus, Buccal mucosa, retromolar trigone, Hard palate, lip

<sup>a</sup>p values by Chi Square test except where indicated

<sup>b</sup>ANOVA

<sup>c</sup>log-rank test; significant p values are in bold

**Publisher's Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.